<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02144714</url>
  </required_header>
  <id_info>
    <org_study_id>SB5-G11-NHV</org_study_id>
    <secondary_id>2013-005332-15</secondary_id>
    <nct_id>NCT02144714</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects</brief_title>
  <official_title>A Randomised, Single-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Three Formulations of Adalimumab (SB5, EU Sourced Humira® and US Sourced Humira®) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Bioepis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Bioepis Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics, safety, tolerability, and
      immunogenicity of SB5 and Humira (EU sourced Humira® and US sourced Humira®) in healthy
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)</measure>
    <time_frame>0 to 1680 hours post-dose</time_frame>
    <description>pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Serum Concentration (Cmax)</measure>
    <time_frame>pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose</time_frame>
    <description>pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>0 to 1680 hours post-dose</time_frame>
    <description>pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose</time_frame>
    <description>pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">189</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SB5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB5, single dose of 40 mg via subcutaneous injection (study drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU sourced Humira®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US sourced Humira®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB5</intervention_name>
    <arm_group_label>EU sourced Humira®</arm_group_label>
    <arm_group_label>SB5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EU sourced Humira®</intervention_name>
    <arm_group_label>SB5</arm_group_label>
    <arm_group_label>US sourced Humira®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>US sourced Humira®</intervention_name>
    <arm_group_label>EU sourced Humira®</arm_group_label>
    <arm_group_label>US sourced Humira®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

          -  Have a body mass index between 20.0 and 29.9 kg/m², inclusive.

        Exclusion Criteria:

          -  History and/or current presence of clinical significant atopic allergy,
             hypersensitivity or allergic reactions, also including known or suspected clinically
             relevant drug hypersensitivity to any components of the test and reference
             investigational product formulation or comparable drugs

          -  Active or latent Tuberculosis or who have a history of Tuberculosis

          -  History of invasive systemic fungal infections or other opportunistic infections

          -  Systemic or local infection, a known risk for developing sepsis and/or known active
             inflammatory process

          -  Serious infection associated with hospitalisation and/or which required intravenous
             antibiotics

          -  History of and/or current cardiac disease

          -  Have received live vaccine(s) within 4 weeks prior to Screening or who will require
             live vaccine(s) between Screening and the final study visit

          -  Intake medication with a half-life &gt; 24 h within 4 weeks or 10 half-lives of the
             medication prior to investigational product administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>May 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <results_first_submitted>January 11, 2018</results_first_submitted>
  <results_first_submitted_qc>January 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 21, 2018</results_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SB5 (Proposed Adalimumab Biosimilar)</title>
          <description>SB5, single dose of 40 mg via subcutaneous injection (study drug)
SB5
EU sourced Humira®</description>
        </group>
        <group group_id="P2">
          <title>EU Sourced Humira®</title>
          <description>EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
SB5
US sourced Humira®</description>
        </group>
        <group group_id="P3">
          <title>US Sourced Humira®</title>
          <description>US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
EU sourced Humira®
US sourced Humira®</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SB5 (Proposed Adalimumab Biosimilar)</title>
          <description>SB5, single dose of 40 mg via subcutaneous injection (study drug)
SB5
EU sourced Humira®</description>
        </group>
        <group group_id="B2">
          <title>EU Sourced Humira®</title>
          <description>EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
SB5
US sourced Humira®</description>
        </group>
        <group group_id="B3">
          <title>US Sourced Humira®</title>
          <description>US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
EU sourced Humira®
US sourced Humira®</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="63"/>
            <count group_id="B4" value="189"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.3" spread="9.55"/>
                    <measurement group_id="B2" value="40.2" spread="11.06"/>
                    <measurement group_id="B3" value="40.0" spread="10.94"/>
                    <measurement group_id="B4" value="39.5" spread="10.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="183"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (cm)</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177.8" spread="6.72"/>
                    <measurement group_id="B2" value="177.5" spread="6.34"/>
                    <measurement group_id="B3" value="177.0" spread="6.68"/>
                    <measurement group_id="B4" value="177.4" spread="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.83" spread="7.163"/>
                    <measurement group_id="B2" value="78.19" spread="6.388"/>
                    <measurement group_id="B3" value="78.12" spread="6.458"/>
                    <measurement group_id="B4" value="78.38" spread="6.651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.98" spread="2.301"/>
                    <measurement group_id="B2" value="24.82" spread="1.823"/>
                    <measurement group_id="B3" value="24.97" spread="1.959"/>
                    <measurement group_id="B4" value="24.93" spread="2.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)</title>
        <description>pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose</description>
        <time_frame>0 to 1680 hours post-dose</time_frame>
        <population>Overall number of participans Analyzed equals to number of subjects who contributed to summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>SB5 (Proposed Adalimumab Biosimilar)</title>
            <description>SB5, single dose of 40 mg via subcutaneous injection (study drug)
SB5
EU sourced Humira®</description>
          </group>
          <group group_id="O2">
            <title>EU Sourced Humira®</title>
            <description>EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
SB5
US sourced Humira®</description>
          </group>
          <group group_id="O3">
            <title>US Sourced Humira®</title>
            <description>US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
EU sourced Humira®
US sourced Humira®</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)</title>
          <description>pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose</description>
          <population>Overall number of participans Analyzed equals to number of subjects who contributed to summary statistics.</population>
          <units>μg·h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2405.6" spread="825.93"/>
                    <measurement group_id="O2" value="2435.5" spread="915.66"/>
                    <measurement group_id="O3" value="2422.6" spread="957.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Serum Concentration (Cmax)</title>
        <description>pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose</description>
        <time_frame>pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose</time_frame>
        <population>Overall number of participans Analyzed equals to number of subjects who contributed to summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>SB5 (Proposed Adalimumab Biosimilar)</title>
            <description>SB5, single dose of 40 mg via subcutaneous injection (study drug)
SB5
EU sourced Humira®</description>
          </group>
          <group group_id="O2">
            <title>EU Sourced Humira®</title>
            <description>EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
SB5
US sourced Humira®</description>
          </group>
          <group group_id="O3">
            <title>US Sourced Humira®</title>
            <description>US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
EU sourced Humira®
US sourced Humira®</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Serum Concentration (Cmax)</title>
          <description>pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose</description>
          <population>Overall number of participans Analyzed equals to number of subjects who contributed to summary statistics.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.365" spread="0.9796"/>
                    <measurement group_id="O2" value="3.548" spread="1.1811"/>
                    <measurement group_id="O3" value="3.488" spread="1.0779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)</title>
        <description>pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose</description>
        <time_frame>0 to 1680 hours post-dose</time_frame>
        <population>Overall number of participans Analyzed equals to number of subjects who contributed to summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>SB5 (Proposed Adalimumab Biosimilar)</title>
            <description>SB5, single dose of 40 mg via subcutaneous injection (study drug)
SB5
EU sourced Humira®</description>
          </group>
          <group group_id="O2">
            <title>EU Sourced Humira®</title>
            <description>EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
SB5
US sourced Humira®</description>
          </group>
          <group group_id="O3">
            <title>US Sourced Humira®</title>
            <description>US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
EU sourced Humira®
US sourced Humira®</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)</title>
          <description>pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose</description>
          <population>Overall number of participans Analyzed equals to number of subjects who contributed to summary statistics.</population>
          <units>μg·h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2125.7" spread="689.92"/>
                    <measurement group_id="O2" value="2096.0" spread="791.28"/>
                    <measurement group_id="O3" value="2101.9" spread="795.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cmax (Tmax)</title>
        <description>pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose</description>
        <time_frame>pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose</time_frame>
        <population>Overall number of participans Analyzed equals to number of subjects who contributed to summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>SB5 (Proposed Adalimumab Biosimilar)</title>
            <description>SB5, single dose of 40 mg via subcutaneous injection (study drug)
SB5
EU sourced Humira®</description>
          </group>
          <group group_id="O2">
            <title>EU Sourced Humira®</title>
            <description>EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
SB5
US sourced Humira®</description>
          </group>
          <group group_id="O3">
            <title>US Sourced Humira®</title>
            <description>US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
EU sourced Humira®
US sourced Humira®</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cmax (Tmax)</title>
          <description>pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose</description>
          <population>Overall number of participans Analyzed equals to number of subjects who contributed to summary statistics.</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.962" spread="89.2503"/>
                    <measurement group_id="O2" value="149.715" spread="76.6421"/>
                    <measurement group_id="O3" value="166.456" spread="79.9227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The PK, safety, tolerability, and immunogenicity assessments were performed for maximum 10 weeks after single-dose administration of SB5, EU sourced Humira®, or US sourced Humira®.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SB5 (Proposed Adalimumab Biosimilar)</title>
          <description>SB5, single dose of 40 mg via subcutaneous injection (study drug)
SB5
EU sourced Humira®</description>
        </group>
        <group group_id="E2">
          <title>EU Sourced Humira®</title>
          <description>EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
SB5
US sourced Humira®</description>
        </group>
        <group group_id="E3">
          <title>US Sourced Humira®</title>
          <description>US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
EU sourced Humira®
US sourced Humira®</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="63"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Samsung Bioepis</name_or_title>
      <organization>Samsung Bioepis</organization>
      <phone>+82 31 8061 4534</phone>
      <email>sbregistry@samsung.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

